Synlogic, Inc. Stock

SYBX

US87166L2097

Biotechnology & Medical Research

Real-time OTC Markets 22:47:03 02/06/2026 HKT			5-day change	1st Jan Change
0.7000 ^USD	+1.45%		-42.62%	-37.50%

08-12	Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Caldera Therapeutics, Inc. entered into an agreement and plan of merger to acquire Synlogic, Inc. for an enterprise value of approximately $500 million in a reverse merger transaction.	CI

Analysts' recommendations : Synlogic, Inc.

21/03/24	HC Wainwright Upgrades Synlogic to Neutral From Sell	MT
09/02/24	Chardan Downgrades Synlogic to Neutral From Buy on Early Termination of Synpheny-3 Trial	MT
09/02/24	Leerink Partners Downgrades Synlogic to Market Perform From Outperform, Adjusts PT to $1 From $6	MT
09/02/24	HC Wainwright Downgrades Synlogic to Sell From Buy	MT
11/12/23	Alliance Global Partners Starts Coverage on Synlogic with Buy Rating, $30 Price Target	MT

More recommendations

Press Releases : Synlogic, Inc.

07-29	Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement	BU
23/12/24	Synlogic : Management Change/Compensation Form 8 K	PU
13/11/24	Synlogic : Reports Third Quarter 2024 Financial Results Form 8 K	PU
13/11/24	Synlogic Reports Third Quarter 2024 Financial Results	AQ
08/08/24	Synlogic Reports Second Quarter 2024 Financial Results	AQ

More press releases

Managers and Directors : Synlogic, Inc.

Manager	Title	Age	Since
Mary Dooley CEO	Chief Executive Officer	45	01/01/2025

Director	Title	Age	Since
Richard Shea BRD	Director/Board Member	74	28/08/2017
Peter Barrett CHM	Chairman	74	28/08/2017
Ed Mathers Mathers BRD	Director/Board Member	66	01/10/2012

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNLOGIC, INC.	+1.45%	-42.62%	-52.05%	-89.63%	13.69M
LONZA GROUP AG	-1.16%	-2.77%	-1.68%	+13.85%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	-0.96%	-2.31%	+15.75%	+45.41%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-1.54%	-1.05%	+12.16%	+29.80%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	-0.72%	+0.43%	+59.73%	+87.61%	27.5B
Weighted average by Cap.	-0.95%	+0.05%	+89.18%	+128.57%

See all sector performances

Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Companyâ€™s preclinical work includes additional metabolic disease research.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	US$1.170	-4.10%	479
03/09/26	US$1.220	-.--%	501

Real-time OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Cap	13.69M 11.77M 11.07M 10.1M 18.9M 1.29B 18.96M 131M 50.73M 663M 51.39M 50.27M 2.11B	P/E 2024	-0.73x	P/E 2025	-13.7x
Enterprise Value	-983K -845K -795K -726K -1.36M -92.96M -1.36M -9.43M -3.64M -47.6M -3.69M -3.61M -152M	EV / Sales 2024	-311x	EV / Sales 2025	-
Free-Float	82.45%	Yield 2024 *	-	Yield 2025	-

08-12	Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Caldera Therapeutics, Inc. entered into an agreement and plan of merger to acquire Synlogic, Inc. for an enterprise value of approximately $500 million in a reverse merger transaction.	CI
05-15	Synlogic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-06	Funicular Fund, LP, a fund managed by Cable Car Capital LLC, submitted a non-binding proposal to acquire remaining 71.69% in Synlogic, Inc. for $5.4 million.	CI
03-13	Synlogic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-23	Synlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI Index	CI
01-20	Synlogic, Inc.(OTCPK:SYBX) dropped from NASDAQ Composite Index	CI
11-27	Synlogic receives letter from Nasdaq listing qualifications department on Nov 21 - SEC filing	RE
11-14	Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
09/08/25	Synlogic Inc files for mixed shelf of up to $150 million - SEC filing	RE
09/08/25	Synlogic Files $150 Million Mixed Shelf	MT
08/08/25	Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/05/25	Synlogic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	+1.45%
1 week	-42.62%
Current month	-42.62%
1 month	-41.67%
3 months	+1.45%
6 months	+18.64%
Current year	-37.50%

1 week	0.7	1.22
1 month	0.7	1.24
Current year	0.54	1.3
1 year	0.54	1.87
3 years	0.54	7.35
5 years	0.54	60.6
10 years	0.54	345

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/7/26	NEA Management Co. LLC	Tax option	Company	-5,281,690	45.1556%
29/10/25	Mary Dooley	Sell	Chief Executive Officer	157	0.0013%
26/4/25	James Flynn	Free	Director	15,000	0.1282%

Synlogic, Inc. Stock

Stocks

SYBX

US87166L2097

Biotechnology & Medical Research

Valuation : Synlogic, Inc.

Chart: Synlogic, Inc.

Latest news : Synlogic, Inc.

Analysts' recommendations : Synlogic, Inc.

Press Releases : Synlogic, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Synlogic, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

	2024	2025
Net sales	8K 6.88K 6.47K 5.91K 11.05K 757K 11.08K 76.72K 29.66K 387K 30.04K 29.39K 1.23M	-
Net income	-23.36M -20.09M -18.89M -17.25M -32.26M -2.21B -32.36M -224M -86.59M -1.13B -87.72M -85.8M -3.6B	-1M -864K -813K -742K -1.39M -95.05M -1.39M -9.64M -3.73M -48.67M -3.77M -3.69M -155M
Net Debt	-18.86M -16.22M -15.26M -13.93M -26.04M -1.78B -26.13M -181M -69.92M -913M -70.83M -69.28M -2.91B	-14.67M -12.61M -11.86M -10.83M -20.26M -1.39B -20.32M -141M -54.38M -710M -55.08M -53.88M -2.26B